WHAT IS CLAIMED IS:

1. A method for inhibiting lg production in a sample of ex vivo peripheral blood mononuclear cells (PBMCs) comprising adding an inhibitory composition to said population.

5 2W 10

A method for treating an autoimmune disorder in a patient comprising:

- a) removing peripherial blood mononuclear cells (PBMC) from said patient;
- b) treating said cells with an inhibitory composition for a time sufficient to suppress Ig production; and
 - c) reintroducing said cells to said patient.
- 3. A method according to claim 1 or 2 wherein said inhibitory composition comprises IL-2.
- 4. A method according to claim 1 or 2 wherein said inhibitory composition comprises a mixture of IL-2 and TGF-β
- 5. A method according to claim 1 or 2 wherein said inhibitory composition comprises a CD2 activator.

A method according to claim wherein said autoimmune disorder is systemic lupus erythematosus (SLE).

20

15

A kit for the treatment of an autoimmune disorder in a patient comprising:

- a) a cell treatment container adapted to receive cells from a patient with an antibody-mediated autoimmune disorder; and
 - b) at least one dose of an inhibitory composition.
- 8. A kit according to claim 7 further comprising written instructions for the method of treating.
- 9. A kit according to claim 7 wherein said dose is contained within said cell treatment container.
 - 10. A kit according to claim 7 wherein said dose is in a lyophilized form.

3

5

- A kit according to claim 7 wherein said cell treatment container further comprises at least one reagent.
- 12. A kit according to claim 7 wherein said cell treatment container further comprises a sampling port to enable the removal of a fraction of said cells for analysis.
- 13. A kit according to claim 7 further comprising an exit port adapted to enable transport at least a portion of said cells to said patient.